SCHEMBL5546687

SCHEMBL5546687

O=COCc1ccc2scccc1-2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.41
DPP4 P27487 4/20 0.40
ERN1 O75460 1/20 0.36
LTK P29376 1/20 0.33
CDK5 Q00535 1/20 0.33
MST1R Q04912 1/20 0.33
DYRK1A Q13627 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
EGFR P00533 1/20 0.33
RET P07949 1/20 0.33
KDR P35968 1/20 0.33
CTRC Q99895 1/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
ALDH1A1 P00352 5/20 0.33
GAA P10253 4/20 0.33
KDM4E B2RXH2 4/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
MAPT P10636 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090951 0.75 LTA4H (0.42) LTA4HDPP4LTKCDK5MST1R
SCHEMBL5539652 0.74 LTA4H (0.53) LTA4HDPP4LTKCDK5MST1R
SCHEMBL5539520 0.73 TP53 (0.36) ERN1KMT2ATP53MAPK1SRC
SCHEMBL2813673 0.71
SCHEMBL2092144 0.71 LTA4H (0.49) LTA4HDPP4LTKCDK5MST1R
SCHEMBL12712165 0.70 KMT2A (0.42) ERN1ALDH1A1GAAKDM4EL3MBTL1
SCHEMBL28257363 0.70 DPP4 (0.42) DPP4KMT2ASRC
SCHEMBL10385976 0.69 LTA4H (0.60) LTA4HDPP4ERN1ADRA1DADRA1A
SCHEMBL9450326 0.69 ALDH1A1 (0.44) LTA4HDPP4ALDH1A1GAAKDM4E
SCHEMBL5544710 0.68 DPP4 (0.48) DPP4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LTA4H 3452/4885DPP4 3965/4885ERN1 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.